Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.
MLYS
14.87 as of 3/28/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 6/8/2022 | Series B | $267.43MM | $XXX.XX | $XXX.XX |
| 4/6/2021 | Series A | $82.36MM | $XXX.XX | $XXX.XX |
